The T-shaped intrauterine device releases levonorgestrel, a hormone that stops the womb lining from thickening and consequently prevents pregnancy.
Women using Kyleena may also experience fewer days of bleeding, while periods may stop altogether for some, according to the report.
Germany-based Bayer, which already offers two other hormonal IUDs, will launch Kyleena in October.
More articles on supply chain:
FDA should remove warning from Pfizer’s drug label, advisory panel says
New bill would require drugmakers to justify price hikes above 10%
Market exclusivity main factor in high drug prices, study finds
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
